295.9K views | +1 today

Abbott lance l’application LibreLink


Le laboratoire Abbott a lancé une application mobile pour permettre aux utilisateurs de FreeStyle Libre d'obtenir leur taux de glucose avec leur smartphone.
No comment yet.

Ad: Are you ready for innovation? The Art of Innovation: How to
Become a “Partner of Choice”


Breakthrough technologies and cutting-edge ideas are the driving force behind innovation. But how can pharma be first in line when researchers and entrepreneurs are looking for new collaborations?
In eyeforpharma's latest thought-piece we explain how you can become the "Partner of Choice" to encourage exciting new partnerships, ensure continued innovation and gain competitive advantages.
With expert insights from:
  • Kemal Malik, Head of InnovationBayer
  • Angel Perez Agenjo, Senior Marketing DirectorLilly
  • Stephan Klaschka, Former Director, Global Innovation Management and StrategyBoehringer-Ingelheim
Find out how you too can partner with leading start-ups and pioneering tech companies by reading the paper today - click here.


No comment yet.

La santé : trop délaissée par les candidats à la présidentielle 2017 #moipatient #hcsmeufr


Alors que la santé est l’une des préoccupations majeures des français, elle semble oubliée dans les campagnes électorales de nos présidentiables de 2017.
No comment yet.



London, Monday 7th November 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 90 patient groups with an interest in heart-and-circulatory conditions. These patient groups came from 35 countries (14 of the 90 were based in Denmark). The report provides feedback (from the perspective of  these patient groups) on the corporate reputation of the entire pharma industry during 2015, as well as on the individual performance of 15 pharma companies at six key indicators that influence corporate reputation. The 2015 heart-and-circulatory results are compared with the responses received in 2014 from patient groups in the same therapy area, as well as with those provided by patient groups from across all therapy areas in 2015.
For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

The 90 heart-and-circulatory patient groups responding to the 2015 ‘Corporate Reputation of Pharma’ survey were more positive about the pharma industry’s corporate reputation than heart-and-circulatory patient groups responding in 2014 (but not as positive as urinary and diabetes patient groups in 2015).

As many as 51.2% of the 90 patient groups with an interest in heart-and-circulatory conditions and responding to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. The equivalent figure for patient groups from across all therapy areas in 2015 was 44.7%. Patient groups with an interest in heart-and-circulatory conditions ranked the pharma industry 4th out of 8 healthcare-industry sectors for corporate reputation in 2015—ahead of private healthcare, generics, and both not-for-profit, and for-profit health insurers. In 2014, heart-and-circulatory patient groups also ranked pharma 4th out of 8 healthcare-industry sectors, but with a much lower average score. Pharma was ranked 5th in 2015’s global results.

Why has pharma’s corporate reputation improved among heart-and-circulatory patient groups? One reason may account for the rise in pharma’s approval ratings among heart-and-circulatory patient groups—pharma’s growing output of innovative medicines. When asked about pharma’s ability to perform specific activities, as many as 80% of 2015’s respondent patient groups with an interest in heart-and-circulatory conditions stated that the industry was “Excellent” or “Good” at making high-quality, useful products. The equivalent figure from heart-and-circulatory patient groups in 2014 was 57%.
Patient groups with an interest in heart-and-circulatory conditions ranked Pfizer overall 1st out of 15 pharma companies for corporate reputation in 2015 (for a second year in a row). They also ranked Pfizer first for two of the six indicators of corporate reputation: patient safety, and the ability to create high-quality products.
Regarding the other four indicators of corporate reputation: AbbVie ranked 1st for patient centricity (the company was not included in 2014’s analyses); Novartis ranked 1st for the provision of patient information; and Sanofi ranked 1st for both transparency and integrity.
The PCRI data for the heart-and-circulatory league tables in 2015 and 2014, and for patient groups from across all therapy areas in 2015, show that Sanofi, Novartis, AstraZeneca, Lilly, and GSK all improved their corporate reputation among heart-and-circulatory patient groups between those two years. The biggest leap was made by Sanofi, which went from 7th out of 11 companies in 2014 to 3rd out of 15 companies in 2015.

Click here for Full contents and tables of the report.

rob halkes's curator insight, November 8, 2016 5:40 AM

Pharma's reputation is rising in heart and circulatory conditions. Pfizer ranks first. See for the full report here:

Takeda announces digital health collaborations to power clinical trials


Pharmaceutical company Takeda is looking to up its digital strategy game, pairing with a few companies to advance clinical trials, analyze data and develop biosensor and wearable technology.Takeda has adopted the platform of Koneska Health, an early stage technology company that works with data gathered through mobile, wearable and other digital technologies to measure health indicators, to power some of the pharmaceutical company’s clinical trials using biosensors and wearables.
No comment yet.

#FDA to Study Space-Limited Communications. Will It Help #Pharma Market Drugs on Twitter & Facebook?


The US Food and Drug Administration (FDA) is planning to study whether links can be sufficient means of presenting risk information about drugs in advertising on social media platforms, such as Twitter, where character space is limited.

"The objective of this research is to test whether a link to prescription drug risk information can effectively convey the risks associated with a drug when benefit claims about the drug are made within character-space-limited communications used in prescription drug promotion," FDA says (here).

To test this theory, FDA says it plans to conduct four studies, two involving Twitter and two using Google sponsored links, to determine how well participants understand and retain risk information depending on whether the information is contained within the communication or merely linked to.

Under current regulations for prescription drug promotion, drugmakers are required to include a balance of information regarding a drug's benefits and risks. However, on many social media platforms the amount of space for text is limited. For instance, Twitter allows just 140 characters per "tweet," making it difficult or impossible for drugmakers to promote their products on the platform.

"The rise of Internet communications that have character space limitations, such as sponsored link promotion and microblog messaging, has led to questions about how to use these communications for prescription drug promotion while complying with the fair balance requirements," FDA says.

While FDA has yet to provide final guidance on pharmaceutical advertising on character-space-limited platforms, the agency's approach in its draft guidance would require risk information in the body of a communication.

"Regardless of character space constraints that may be present on certain Internet/social media platforms, if a firm chooses to make a product benefit claim, the firm should also incorporate risk information within the same character-space-limited communications. The firm should also provide a mechanism to allow direct access to a more complete discussion of the risks associated with its product," the draft guidance states.

However, many in industry have argued that risk information can be presented effectively by including a link to a page that discusses the benefits and risks of a product more fully, and that including risk information in the communication itself is unnecessary (for more on that, read: "Overcoming Space Limitations in Social Media";

Pharma Guy's curator insight, November 8, 2016 12:21 PM

Related article: “Survey Results: FDA's Regulation of Drug & Device Promotion via the Internet & Social Media”;

The rise of the Chief Digital Officer | Deloitte Digital Canada


As rapidly evolving digital technologies continue to alter the business landscape, a new and important executive is moving into the C-suite neighbourhood: the Chief Digital Officer (CDO).
No comment yet.

How content marketing is helping Philips move into healthcare


Blake Cahill, global head of digital and social at Philips, explains how content marketing is playing a key role in the brand's transformation into a healthcare company.
No comment yet.

Pharma et e-santé : comment l'industrie pharmaceutique investit l’e-santé ?


Le digital devient une partie intégrante du modèle économique des laboratoires pharmaceutiques et ce faisant, devrait modifier en profondeur les usages du secteur.

No comment yet.

Marketing et communication digitale : quels métiers et quelles compétences en 2016 ?


Marketing, communication : après les social media managers et les chefs de projets, voici venu les CX designers et autres Chiefs Experience Officers.
No comment yet.

Mixez les compétences pour construire votre plateforme digitale


La technologie est abondante. La transformation numérique de l'entreprise est dans ses usages. Mixez les compétences technologiques e
No comment yet.

Propeller Health's digital health platform gains FDA clearance for use with GlaxoSmithKline's Ellipta inhaler


Propeller Health announced Monday the FDA clearance to market its Propeller digital health platform for use with GlaxoSmithKline's Ellipta dry powder inhaler.

No comment yet.

Big Tech And Pharma Bet On Cancer Therapy Startups: Celgene, Novartis, Pfizer, and Google’s Investments


Celgene has backed more than 15 companies since 2012. Google Ventures joined the list of top investors this year.
No comment yet.

The Power of Human-Centered Technology: 4 Johnson & Johnson Innovations That Could Help Revolutionize Your Health


Find 4 healthcare innovations from Johnson & Johnson that are poised to make digital waves in the healthcare technology space.
No comment yet.

Transformation digitale : entre révolution culturelle et raisons de s'inquiéter


Les entreprises les plus avancées en digital ont vraiment une bonne approche du sujet mais l'écart avec les autres se creuse de manière dangereuse
No comment yet.

Digitalisation des grandes entreprises : Encore pas mal de blocages à lever | Le blog du Communicant


Acteur européen de la transformation digitale, Econocom a publié récemment le Baromètre des pratiques digitales 2016 des entreprises françaises réalisé par
No comment yet.

Teva et IBM souhaitent utiliser l’Intelligence artificielle pour faire avancer la médecine


Les deux sociétés ont annoncé qu’ils allaient étendre leur alliance en e-santé grâce au IBM Watson Health Cloud
Bruno Demay's curator insight, November 1, 2016 12:17 PM

Les fonctions cognitives et prédictives de Watson intéressent particulièrement la santé: de nouveaux partenariats attendus dans les prochains mois....

IBM Watson & Celgene Partner to Bring Pharmacovgilance Into the Modern "Smart" Digital Era!


Celgene and IBM are teaming up on a new patient safety monitoring platform to improve pharmacovigilance methods throughout the drug development process.

The platform, dubbed IBM Watson for Patient Safety, will combine Watson’s cognitive computing chops with Celgene’s extensive experience in drug safety and risk management. It will be an outcome- and evidence-based drug safety decision support system for life sciences companies, the duo said in a statement.

It will run on the Watson Health Cloud. The highly automated, modular, end-to-end drug safety platform will allow for the rapid collection, collation and automated analysis of vast amounts of data from a variety of sources, the companies said in a statement. It will help biopharmaceutical companies better manage and interpret large volumes of data relating to potential side effects associated with drug products, they said.

“For a long time, very big decisions around the use and disposition of drugs have been taken based on small datasets,” said John Freeman, corporate vice president of global drug safety and risk management at Celgene. “This is an opportunity to not only streamline the way that information is handled within pharma companies and regulators, but also to enable much greater clarity of insight born of an ability to access large datasets.”

IBM Watson for Patient Safety will use cognitive computing to understand structured and unstructured language and therefore use a lot of different sources to help in making decisions, said Lauren O’Donnell, vice president of life sciences at IBM Watson Health. These include anonymized electronic medical records and medical claims databases. In addition to analyzing and identifying trends in large datasets, IBM Watson also learns. And the case numbers are only continuing to grow: Between 2008 and 2011 alone, there was a 90% increase in serious adverse events recorded, she said.

While the obvious applications are for decision-making in the early stages of drug development, leading to greater efficiencies while developing products, there are also advantages post-commercialization, Freeman said. The platform can help patients who are at greater risk of side effects manage their condition better and reduce the likelihood of those side effects.

“Celgene established one of the first risk management systems and its commitment to pharmacovigilance continues with this partnership,” O’Donnell said in the statement. “Together we look forward to creating a cognitive solution that can be applied across the industry to help benefit patients everywhere.”

No comment yet.

AI Takes On Drug Safety


IBM Watson Health tries to do what no pharma company has done: solve the drug-safety puzzle.

Big Blue has found yet another business application for its precocious cognitive computing system. IBM Watson Health is collaborating with the biopharmaceutical company Celgene to develop a new platform for evaluating the safety of drugs—both before and after they hit the market—the two companies are announcing this morning. The new offering,


Watson for Patient Safety,” will gobble up anonymized medical records, claims data, and millions of electronic submissions to the FDA about potential drug side effects (known as individual case safety reports) to see if it can learn about the hidden dangers of medicines before they become too costly.

Jim Murphy's curator insight, November 3, 2016 7:57 AM
This is a fabulous application of big data in action

Pharma ramps up its use of Instagram


More than half of big pharma now uses Instagram in some form, though companies' corporate accounts - traditionally the first to be set up - are just behind that milestone.


The most recent of those to launch a corporate presence is GlaxoSmithKline, which joined the photo sharing social network last month promising to “explore what's behind the science and discover some of the latest healthcare innovations”.

GSK joins the likes of Novartis, Pfizer, Sanofi and Teva in having a companyInstagram account, and in total nine of the top 20 firms have followed this route.


Pushing the industry's use of Instagram just over the 50% mark (11 out of the top 20 companies) are careers accounts from Merck & Co and AstraZeneca.

Acquired by Facebook in 2012, Instagram has a long way to go before it challenges its parent company's dominance, but - with its user base heavily skewed towards a younger demographic - it comes second for reach and use among those under 35. 

For those 35 and older, US research carried out in December 2015 by comScore places it second for use but behind LinkedIn, Twitter and Google+ when it comes to reach.


In reviewing pharma's use of Instagram it can be seen that a number of companies' names are already in use … just not by them - a familiar social media issue for companies and brands that don't move quickly enough when new channels emerge.

Consequently, the likes of AstraZeneca, AbbVie, Amgen and Astellas may need to be a little bit creative with their user names should they want to sign-up.

No comment yet.

Technology Will Save Healthcare, But Who Will Successfully Implement the Needed Changes? Pharma or Tech Companies?


It is a fact that healthcare is unsustainable. American health spending will reach nearly $5 trillion, or 20 percent of gross domestic product by 2021. The World Health Organization (WHO) estimates that there is a worldwide shortage of around 4.3 million physicians, nurses, and allied health workers. So how could we change it?

The most likely solution is technology. The introduction of artificial intelligence, robotics, social media, various sensors and wearables in medicine could save millions of lives and reduce costs at the same time. There is one question, however, which needs to be answered. Who can and should provide these new technologies for the advancement of humanity?

So, where are pharmaceutical and medical companies in this story? Shouldn’t they ensure the smooth advancement towards the paradigm-shift from offline to digital healthcare?

Well, the question is a little bit more complex. Pharmaceutical companies have decades-long experience in healthcare but most of them are still struggling with adopting new technologies. This is just not their strongest arm. Some new medical companies are good at adopting technology, but have no experience in introducing breakthrough changes into healthcare. As most of the changes healthcare faces in the coming years are centered on digital solutions, technology companies have a competitive advantage.

Based on this logic, the inevitable response would be that technological companies could provide the innovative ideas and solutions which are necessary in order to change healthcare and lead it into the 21st or 22nd century.

But the picture is not all rosy.

coalescebargemaster's comment, October 31, 2016 11:44 PM
Thats magnificent...

@Richmeyer Calls for Resurrection of George Merck - a #Pharma CEO Who Put Patients Before Profits


The biggest challenge facing pharma, and all healthcare for that matter, is the drive for increased profit at the expense of patients. Unless pharma acknowledges that they need to put patients first in everything they do, they are going to pay the price in increased calls for a “single payer” system.


Following Digital Pharma in social media I was reminded that there still are a lot of very good people in the industry who understand the challenge of marketing to patients today. However, like I wrote before, there is a disconnect between developing a strategy and actually implementing it.


When I see the salaries of pharma CEO’s and health insurance executives I am often troubled and confused. How could a health insurance CEO take home tens of millions of dollars in compensation when they raise rates for customers? How can a pharma CEO take home so much money knowing that there are some patients who can’t afford their medications?


DTC marketers know what they need to do to make their marketing relevant to their audience, but they often lack the budgets to make it happen. Everything is now based on ROI instead of asking “how can we help patients?”. Offering a medication to fight chronic health problems is not enough. Patients today need help from a healthcare system that treats them as a number not a person. They are left to fend for themselves when it comes to understanding how to live with health issues that affect their lives.


A new breed of pharma CEO is needed. Someone who can tell Wall Street that what we are doing to help patients will lead to better profits and someone who doesn’t ask for a compensation package that makes them a millionaire ten times over. Most importantly, we need CEO’s that allow the rank and file to implement programs that actually embrace patients based on their needs rather than a projected ROI.

Pharma Guy's curator insight, October 31, 2016 1:26 PM

When was the last time a big pharma CEO was featured on the cover of Time magazine (does that mag still exist?). Unfortunately Merck has rewritten its founder's words: "We try to remember that medicine is for the patient investor. We try never to forget that medicine is for the people investors. It is not IS for the profits. The profits follow lead, and if we have remembered that, they will never fail to appear. The better we have remembered that, the larger they have been." – George Corporate Merck. For more on that, read “Merck in the Mirror: Profits, Not People, Come First. Shame!”;

Bayer's Betaseron Facebook Ad Uses a New Feature: Scrolling ISI


Bayer’s Facebook ad campaign for multiple sclerosis drug Betaseron and its Betaconnect injector launched this month with several firsts. It's not only Bayer’s first Facebook ad, but it's also the first time Facebook has enabled a scrolling ISI inside a pharma ad.


Scrolling safety information allowed Bayer to stay inside text and photo limits of a pre-determined ad box but still meet FDA guidelines for necessary risk information. While some pharmas already do that in banner ads, it had not been done inside Facebook ads until this campaign, said Craig Hashi, Facebook Health client partner, who--along with Ozgun Demir, associate director of emarketing at Bayer--talked about the work at the Digital Pharma East conference last week.


Another new feature of the ad is the “call now” button, a feature Facebook added last year for business ads. However, for the Betaconnect ad, the phone button is connected to a live nursing-staffed line. To accommodate the real-time interaction, the ad was set up to run only between the weekday hours of 8 a.m. to 8 p.m.


The Betaconnect Facebook campaign is using Lead Ads, which allows users to click to sign up for more information without leaving the site and with the ability to input the person's Facebook account data, such as name and email address, into the form. Going from the initial idea for the ad to publish took about four weeks, Hashi said.

coalescebargemaster's comment, October 31, 2016 11:43 PM
Thats incredibly good...